Napp Pharmaceuticals says the UK is the first country in Europe to launch flutiform k-haler, a breath-actuate inhaler for adolescents and adults living with asthma. More: UK first EU nation to launch flutiform k-haler for asthma Source: News
read moreAstraZeneca and Amgen’s tezepelumab has won breakthrough therapy status in the US for its potential to treat severe asthma without an eosinophilic phenotype. More: AstraZeneca, Amgen’s tezepelumab wins ‘breakthrough’ status Source: News
read moreThe MS Society has launched a petition imploring the National Institute for Health and Care Excellence, NHS England and Roche to come to an agreement on NHS availability of Ocrevus for primary progressive multiple sclerosis (PPMS). More: MS Society launches
read moreGlaxoSmithKline’s bid to expand the use of its biologic Nucala in the US to include patients with coronary pulmonary obstructive disorder (COPD) has hit a significant setback. More: US regulators reject GSK’s Nucala for COPD Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals